BR112012008483A2 - combunações de um inibidor de pi3k e um inibidor de mex - Google Patents

combunações de um inibidor de pi3k e um inibidor de mex

Info

Publication number
BR112012008483A2
BR112012008483A2 BR112012008483A BR112012008483A BR112012008483A2 BR 112012008483 A2 BR112012008483 A2 BR 112012008483A2 BR 112012008483 A BR112012008483 A BR 112012008483A BR 112012008483 A BR112012008483 A BR 112012008483A BR 112012008483 A2 BR112012008483 A2 BR 112012008483A2
Authority
BR
Brazil
Prior art keywords
inhibitor
mex
combinations
pi3k
pi3k inhibitor
Prior art date
Application number
BR112012008483A
Other languages
English (en)
Portuguese (pt)
Inventor
T Chan Iris
Wallin Jeffrey
Prescott John
P Hoeflich Klaus
Friedman Lori
Belvin Marcia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012008483(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012008483A2 publication Critical patent/BR112012008483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112012008483A 2009-10-12 2010-10-11 combunações de um inibidor de pi3k e um inibidor de mex BR112012008483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Publications (1)

Publication Number Publication Date
BR112012008483A2 true BR112012008483A2 (pt) 2019-09-24

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008483A BR112012008483A2 (pt) 2009-10-12 2010-10-11 combunações de um inibidor de pi3k e um inibidor de mex

Country Status (24)

Country Link
US (1) US20110086837A1 (enExample)
EP (1) EP2488178B1 (enExample)
JP (2) JP2013507415A (enExample)
KR (1) KR101489045B1 (enExample)
CN (1) CN102740851B (enExample)
AR (1) AR078588A1 (enExample)
AU (1) AU2010314287A1 (enExample)
BR (1) BR112012008483A2 (enExample)
CA (1) CA2776944A1 (enExample)
CL (1) CL2012000913A1 (enExample)
CO (1) CO6531463A2 (enExample)
CR (1) CR20120173A (enExample)
EC (1) ECSP12011865A (enExample)
ES (1) ES2609767T3 (enExample)
IL (1) IL219105A0 (enExample)
MA (1) MA33974B1 (enExample)
MX (1) MX345155B (enExample)
NZ (1) NZ599939A (enExample)
PE (1) PE20121816A1 (enExample)
PH (1) PH12012500709A1 (enExample)
RU (1) RU2563193C2 (enExample)
TW (1) TWI428336B (enExample)
WO (1) WO2011054620A1 (enExample)
ZA (1) ZA201202618B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
PT3111938T (pt) 2011-04-01 2019-07-10 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
JP6062442B2 (ja) 2011-10-13 2017-01-18 ジェネンテック， インコーポレイテッド 薬剤誘発性低酸症の治療
KR20140097205A (ko) * 2011-10-28 2014-08-06 제넨테크, 인크. 흑색종을 치료하는 치료 조합물 및 방법
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN104334192A (zh) * 2012-04-06 2015-02-04 赛诺菲 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
WO2013157648A1 (ja) * 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014022680A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014152358A2 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EP3193902A4 (en) * 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
EP3849554B1 (en) 2018-09-11 2025-01-29 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
AU685933B2 (en) * 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU7349801A (en) * 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. ｐ38 억제제 및 그의 사용 방법
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
PE20081679A1 (es) * 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
BRPI0816769A2 (pt) * 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Also Published As

Publication number Publication date
US20110086837A1 (en) 2011-04-14
KR20120064132A (ko) 2012-06-18
PH12012500709A1 (en) 2012-10-29
CO6531463A2 (es) 2012-09-28
EP2488178B1 (en) 2016-11-16
KR101489045B1 (ko) 2015-02-02
CR20120173A (es) 2012-07-04
TW201118082A (en) 2011-06-01
JP5745678B2 (ja) 2015-07-08
MX345155B (es) 2017-01-18
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
JP2013507415A (ja) 2013-03-04
IL219105A0 (en) 2012-06-28
AR078588A1 (es) 2011-11-16
CN102740851A (zh) 2012-10-17
AU2010314287A1 (en) 2012-05-03
MA33974B1 (fr) 2013-02-01
WO2011054620A1 (en) 2011-05-12
ECSP12011865A (es) 2012-06-29
ES2609767T3 (es) 2017-04-24
CN102740851B (zh) 2013-12-18
CA2776944A1 (en) 2011-05-12
AU2010314287A2 (en) 2012-07-12
JP2015038110A (ja) 2015-02-26
EP2488178A1 (en) 2012-08-22
NZ599939A (en) 2014-02-28
ZA201202618B (en) 2014-10-29
PE20121816A1 (es) 2013-01-02
RU2012118974A (ru) 2013-11-20
HK1175125A1 (en) 2013-06-28
CL2012000913A1 (es) 2012-09-14
TWI428336B (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
EP2480576A4 (en) PCSK9 ANTAGONISTS
DK2448938T3 (da) Pyrimidinoner som pi3k-inhibitorer
EP2414948A4 (en) APPLICATION SHARING
EP2518066A4 (en) NOVEL THROMBOCYTE AGGREGATION INHIBITOR
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
SMT201500271B (it) Inibitori di neprilisina
EP2488033A4 (en) COMBINATION
EP2442711A4 (en) DETERMINATION OF HEMODYNAMIC PERFORMANCE
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
BRPI0918564A2 (pt) inibidores
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
EP2478768A4 (en) AGGREGATE AGAINST PLANT VIRUSES
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
BRPI1011267A2 (pt) inibidores de protease
DK2453858T3 (da) Fremgangsmåde
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DK2516435T3 (da) Inhibitorer af AKT-aktivitet
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
EP2480076A4 (en) IMIDOTHIAZOLKINASEINHIBITOREN
EP2242714A4 (en) Protective insert

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.